NCT05671835

Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis

REVERT-IPF: A Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 100 (actual)
• Sponsor: Tvardi Therapeutics, Incorporated · Industry
• Sex: All
• Age: 40 Years
• Healthy volunteers: Not accepted

Summary

The primary objective of this study is to evaluate the safety and tolerability of oral daily administration of TTI-101 over a 12-week treatment duration in participants with idiopathic pulmonary fibrosis (IPF).

Conditions

• Idiopathic Pulmonary Fibrosis

Interventions

Type	Name	Description
DRUG	TTI-101	Orally via a tablet.
DRUG	Placebo	Orally via a tablet.

Timeline

• Start date: 2023-05-15
• Primary completion: 2025-08-14
• Completion: 2025-08-14
• First posted: 2023-01-05
• Last updated: 2025-09-30

Locations

28 sites across 1 country: United States

Regulatory

• FDA-regulated drug study